Sarepta Therapeutics Faces Existential Crisis Amid Mounting Challenges

Biotechnology firm Sarepta Therapeutics is confronting the most severe crisis in its corporate history. A combination of regulatory rejections for its promising gene therapy ELEVIDYS, a surge of litigation, and tragic patient fatalities has sent the company’s stock into a downward spiral, raising fundamental questions about its ability to survive.

Financial Restructuring and Mounting Legal Pressure

In a bid to achieve financial stability, Sarepta is undertaking urgent measures to restructure $700 million in convertible debt due in 2027. The company is refinancing this into new bonds carrying a higher interest rate and maturing in 2030. This complex deal, which also includes equity issuance and cash components, is slated for completion on August 28th. However, the proposed new conversion price of $60 per share appears highly optimistic given the stock’s current depressed trading levels.

Simultaneously, the company’s legal troubles are reaching a critical juncture. The deadline for class-action lawsuits against Sarepta closes today, Monday. These suits collectively allege the company misled investors regarding safety risks associated with ELEVIDYS. The central accusations claim the firm inadequately documented severe adverse effects during clinical trials and made positive efficacy statements that lacked a factual foundation.

Should investors sell immediately? Or is it worth buying Sarepta Therapeutics?

Patient Tragedies and European Regulatory Rejection

The wave of litigation was triggered by three patient deaths occurring within months of each other. The first tragedy, an acute liver failure death following ELEVIDYS treatment in March 2025, caused an immediate sharp decline in the share price. Subsequent fatalities in June and July led to the suspension of therapy deliveries and a dosing halt in ongoing studies, profoundly shaking investor confidence.

Compounding these crises, Sarepta suffered a significant regulatory setback in July 2025 when the European Medicines Agency (EMA) denied marketing authorization for ELEVIDYS. The agency’s decision was based on devastating clinical trial data: a study of 125 children aged 4 to 7 years showed no significant difference in outcomes between the treatment group and those receiving a placebo. The measured improvements in motor function were so minimal they lacked statistical relevance, effectively shattering the company’s ambitions for European expansion.

The confluence of these events—regulatory denials, serious safety incidents, and drastic financial maneuvers—places the entire viability of Sarepta Therapeutics in doubt. As management struggles to steady the company, investors are left questioning whether this represents a potential turnaround story or the beginning of a terminal decline.